One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Rivkin, S E, Green, S, Metch, B, Jewell, W R, Costanzi, J J, Altman, S J, Minton, J P, O'Bryan, R M, Osborne, C KVolume:
11
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.1993.11.9.1710
Date:
September, 1993
File:
PDF, 575 KB
english, 1993